MAP2K7 and neoplasm: Six patients (16.7%) presented with tumor recurrence after a mean of 35 ​± ​29 months; 2 were treated with TCA, 1 with EEA, 1 with photon radiation therapy, and another with proton therapy followed by chemotherapy with BRAF/MEK pathway inhibitors for multiple disseminations through the CSF.